Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...
REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
According to Benzinga Pro, Regeneron Pharmaceuticals Inc's peer group average for short interest as a percentage of float is ...
Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...
Investing.com - Regeneron Pharma (NASDAQ: REGN) reported third quarter EPS of $11.83, $2.19 better than the analyst estimate of $9.64. Revenue for the quarter came in at $3.75B versus the consensus ...
Fintel reports that on October 29, 2025, Guggenheim maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...
Fintel on MSN
B of A Securities Maintains Regeneron Pharmaceuticals (REGN) Underperform Recommendation
Fintel reports that on October 29, 2025, B of A Securities maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback